ArticleScientific reports2019
Genomic Landscape of Intramedullary Spinal Cord Gliomas.
Article in Scientific reports, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04211974 (Genomic Landscape of Intramedullary Astrocytoma), which is not on this map. Cited by 22 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Genomic Landscape of Intramedullary Astrocytoma
Who cites it
22 citing papers in PubMed, 1 synthesis or guideline pooled it, 37 citations in OpenAlex.
- Diffuse Midline H3K27-Altered Gliomas in the Spinal Cord: A Systematic Review.Journal of neuro-oncology · 2024Pooled it
- Characterizing intradural spinal metastasis in the metastatic cascade: clinical course, dissemination timing, and molecular features in 69 patients.Journal of neuro-oncology · 2026Article
- Article
- Liquid Biopsy for Spinal Tumors: On the Frontiers of Clinical Application.Global spine journal · 2025Article
- Astrocytomas of the spinal cord.Neuro-oncology advances · 2024Review
- Article
- Transcriptomic and epigenetic dissection of spinal ependymoma (SP-EPN) identifies clinically relevant subtypes enriched for tumors with and without NF2 mutation.Acta neuropathologica · 2024Article
- Intramedullary Spinal Cord Tumors: Whole-Genome Sequencing to Assist Management and Prognosis.Cancers · 2024Article
- Review
- Tumor microenvironment in a minipig model of spinal cord glioma.Journal of translational medicine · 2023Article
- The biology of ependymomas and emerging novel therapies.Nature reviews. Cancer · 2022Review
- Surgical approaches to intramedullary spinal cord astrocytomas in the age of genomics.Frontiers in oncology · 2022Review
- Transcriptomic Portraits and Molecular Pathway Activation Features of Adult Spinal Intramedullary Astrocytomas.Frontiers in oncology · 2022Article
- Expression profile of RNA binding protein in cervical cancer using bioinformatics approach.Cancer cell international · 2021Article
- Analyses of DNA Methylation Profiling in the Diagnosis of Intramedullary Astrocytomas.Journal of neuropathology and experimental neurology · 2021Article
- Molecular diagnostics helps to identify distinct subgroups of spinal astrocytomas.Acta neuropathologica communications · 2021Article
- Integrated analysis of the functions and prognostic values of RNA-binding proteins in neuroblastoma.PloS one · 2021Article
- Ganglioglioma of the cervicothoracic spinal cord in a patient with neurofibromatosis type 1: A case report.Surgical neurology international · 2021Article
- Surgical treatment and neurological outcome of infiltrating intramedullary astrocytoma WHO II-IV: a multicenter retrospective case series.Journal of neuro-oncology · 2021Article
- Clinical, radiological and molecular characterization of intramedullary astrocytomas.Acta neuropathologica communications · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors at 2 institutions in 1 country.
Funding
Abstract
Intramedullary spinal cord tumors (IMSCTs) are rare neoplasms that have limited treatment options and are associated with high rates of morbidity and mortality. To better understand the genetic basis of these tumors we performed whole exome sequencing on 45 tumors and matched germline DNA, including twenty-nine spinal cord ependymomas and sixteen astrocytomas. Though recurrent somatic mutations in IMSCTs were rare, we identified NF2 mutations in 15.7% of tumors (ependymoma, N = 7; astrocytoma, N = 1), RP1 mutations in 5.9% of tumors (ependymoma, N = 3), and ESX1 mutations in 5.9% of tumors (ependymoma, N = 3). We further identified copy number amplifications in CTU1 in 25% of myxopapillary ependymomas. Given the paucity of somatic driver mutations, we further performed whole-genome sequencing of 12 tumors (ependymoma, N = 9; astrocytoma, N = 3). Overall, we observed that IMSCTs with intracranial histologic counterparts (e.g. glioblastoma) did not harbor the canonical mutations associated with their intracranial counterparts. Our findings suggest that the origin of IMSCTs may be distinct from tumors arising within other compartments of the central nervous system and provides the framework to begin more biologically based therapeutic strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.